{"id":146684,"date":"2026-04-24T15:05:41","date_gmt":"2026-04-24T19:05:41","guid":{"rendered":"https:\/\/medcitynews.com\/?p=146684"},"modified":"2026-04-24T15:05:41","modified_gmt":"2026-04-24T19:05:41","slug":"kurma-partners-fund-venture-capital-biotech-investing-startups-europe","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/","title":{"rendered":"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019"},"content":{"rendered":"

Biotechnology-focused venture capital firm Kurma Partners has closed a new fund with \u20ac215 million<\/a> (about $252 million) in fresh capital to deploy across up to 20 young companies in the life sciences.<\/p>\n

Paris-based Kurma said its new fund is its fourth and largest, topping the firm\u2019s third fund, which totaled \u20ac160 million (about $186 million). But the latest fund\u2019s total is short of the \u20ac250 million (about $292 million) target Kurma set when it announced the fund\u2019s first close in 2024<\/a>.<\/p>\n

Kurma said the new fund will support investments in companies focused on discovery and development of \u201cdisruptive therapeutic solutions for severe or incurable diseases.\u201d On its website, Kurma says<\/a> about 80% of Biofund IV will be invested in its portfolio companies developing new therapies. Up to half of the fund\u2019s investments will go to companies established by the management company or ArgoBio Studio, a startup launchpad co-founded by Kurma and Bpifrance.<\/p>\n

Kurma was founded in 2009. Investments from the firm\u2019s third fund have led to three exits: the 2021 acquisition of Corlieve Therapeutics<\/a> by uniQure, Eli Lilly\u2019s 2023 acquisition of Emergence Therapeutics<\/a>, and AstraZeneca\u2019s 2024 buyout of Amolyt Pharma<\/a>.<\/p>\n

In 2021, Eurazeo acquired a majority stake in Kurma. Last year, that investment firm acquired<\/a> the remaining Kurma shares. In its most recent financial report, publicly traded Eurazeo said its assets under management totaled \u20ac39 billion (about $45.6 billion).<\/p>\n

Eurazeo is one of the investors in the new Kurma fund. Kurma said the fund\u2019s three \u201ccornerstone investors\u201d are Australian biotech company CSL Limited, the European Investment Fund, and Bpifrance. Kurma said other entities putting cash into the new fund include European institutional investors and family offices.<\/p>\n

The Kurma portfolio currently lists close to 60 companies working in areas such as autoimmune disease, cancer, heart disease, and respiratory conditions. Kurma said the new fund has already invested in 11 companies. Most of them are based in Europe, but Kurma notes on its website that it also invests in other regions. For example, earlier this year Kurma participated in the Series A financing of obesity drug developer Alveus Therapeutics<\/a>, a startup that splits its operations between Philadelphia and Copenhagen.<\/p>\n

With the close of the new fund, Kurma said its assets under management now total \u20ac1 billion (about $1.1 billion). In the Thursday announcement of the fund close, Kurma Managing Partners Thierry Laugel and R\u00e9mi Droller said the latest close reflects investor trust in the firm\u2019s investment model.<\/p>\n

\u201cWith Biofund IV and Argobio Studio, we now possess a unique capacity in Europe to identify world-class academic science, transform it into globally competitive biotechnology companies, and support them through to full maturity,\u201d they said.<\/p>\n

Photo: Dimitrios Kambouris\/Getty Images for Victoria’s Secret<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Kurma Partners\u2019 new fund is the venture capital firm\u2019s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma. <\/p>\n","protected":false},"author":25932,"featured_media":20436,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[60,69],"hide_from_feed":false,"footnotes":""},"categories":[69,60],"tags":[42355,7758,53587,8316,6369],"class_list":["post-146684","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-startup-channel","tag-biopharma-nl","tag-investing","tag-kurma-partners","tag-startups","tag-venture-capital"],"acf":[],"yoast_head":"\nVC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019 - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019 - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Kurma Partners\u2019 new fund is the venture capital firm\u2019s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T19:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"467\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019\",\"datePublished\":\"2026-04-24T19:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/\"},\"wordCount\":452,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg\",\"keywords\":[\"biopharma nl\",\"investing\",\"Kurma Partners\",\"Startups\",\"Venture Capital\"],\"articleSection\":[\"BioPharma\",\"Startups\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/\",\"name\":\"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019 - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg\",\"datePublished\":\"2026-04-24T19:05:41+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg\",\"width\":700,\"height\":467},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019 - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/","og_locale":"en_US","og_type":"article","og_title":"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019 - MedCity News","og_description":"Kurma Partners\u2019 new fund is the venture capital firm\u2019s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.","og_url":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/","og_site_name":"MedCity News","article_published_time":"2026-04-24T19:05:41+00:00","og_image":[{"width":700,"height":467,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019","datePublished":"2026-04-24T19:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/"},"wordCount":452,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg","keywords":["biopharma nl","investing","Kurma Partners","Startups","Venture Capital"],"articleSection":["BioPharma","Startups"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/","url":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/","name":"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019 - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg","datePublished":"2026-04-24T19:05:41+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2019\/06\/ParisEiffel-e1561146081131.jpg","width":700,"height":467},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/04\/kurma-partners-fund-venture-capital-biotech-investing-startups-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"VC Firm Kurma Partners Closes \u20ac215M Fund in Pursuit of \u2018Disruptive Therapeutic Solutions\u2019"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=146684"}],"version-history":[{"count":1,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146684\/revisions"}],"predecessor-version":[{"id":146685,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146684\/revisions\/146685"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/20436"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=146684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=146684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=146684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}